TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.

• Status: Unknown status
• Trial end date: 2019-09-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy TONKA on the reduction of ALT and AST in moderate to severe liver enzyme elevated patients; compared with Silymarin (Legalon) after 6 weeks of treatment.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nhat Nhat Pharmaceutical Company
• Treatments: Silymarin

Criteria

Inclusion Criteria:

• Male and Female more than 18 year old.

• Diagnosed as Alcoholic Liver Disease (ALD), or Non Alcoholic Fatty Liver Disease (NAFLD), or Liver Function Disorders due to Drugs or Chemicals.

• ALT at baseline is in between 150 U/L to 400 U/L

• Sign the informed consent form

Exclusion Criteria:

• Hepatitis B or C.

• Pregnant or Lactating women